Villeda Cabrera Isaac

THE FUTURE ROLE OF CARDIO-

ONCOLOGISTS

Wide Spectrum of Conclusion

Cardiovascular
Complications of
Cancer Treatment
The first clinical manifestation
of adverse effects from
anticancer drugs on the CV
system was depression of the
left ventricle function
Rates of CV problems from
cancerrelated
therapeutics have been
reported to be in excess of 30 %,
and cardiotoxicity is the second
most common cause of morbidity
and mortality in cancer survivors
Complexity of the cancer treatment requires
tight cooperation between oncologist and
Basic Concept for the
cardiologist in the identification of at-risk
Management of Patients
patients, planning of treatment, and These are the processes
Treated with Potentially
patient surveillance with the aimsto prevent that must be led by
Cardiotoxic Drugs
cardiotoxicity, detect early signs of medical societies in a
cardiotoxicity and to take appropriate discussion with other
measures to solve complications partners involved in the
treatment of oncological
There are four patients: healthcare
Therefor
factors areCVfour
risk:
providers, the healthcare
factors for CV risk:
current myocardial industry, health insurers,
current myocardial
disease Cardio-oncology institutions involved in
disease
Clinic healthcare and the general
public.
current
currentmyocardial
myocardialdisease
disease key components for
previous
previous cardiotoxiccancer
cardiotoxic cancer the effective work of
treatment
treatment demographicrisk
demographic risk High level of
the cardio-oncology
factors
factorslife-style
life-stylerisk
riskfactors
factors programme
centre
leadership
Appropriate location
Experienced staff
CV testing